DYSLIPIDEMIA IN PATIENTS WITH DIABETIC KIDNEY DISEASE. OBJECTIVES OF TREATMENT. USE OF LIPID-LOWERING DRUGS

Abstract

The dyslipidemia rate in patients with chronic kidney disease (CKD) was demonstrated over 60%, presenting lipidic variations proatherogenic with qualitative alterations more significant than quantitative ones in the global cardiovascular risk, apart from the LDL. For the pharmacological treatment, statins or statin/ ezetimibe combination play a fundamental role either for the improvement of lipid profile or for the reduction of cardiovascular events (CVE), however, the dose should be adjusted with relation to pharmacological interactions. The pharmacological treatment with lipid lowering drugs in patients with more ad- vanced chronic kidney disease (CKD) is still under discussion. In patients with CKD, the cholesterol levels not always present a linear relations with cardiovascular events, as with the general population. In patients with kidney disease and diabetes, the target LDL should be <100 mg/dl, and for those with CVE and diabetic kidney disease <70 mg/dl.

Keywords

• enfermedad renal crónica
• dislipemias
• hipolipemiantes
• eventos cardiovasculares
• enfermedad renal diabética